Literature DB >> 11981308

Invasive pulmonary aspergillosis.

Ilana Oren1, Noam Goldstein.   

Abstract

Invasive pulmonary aspergillosis is the most common fungal pulmonary infection in certain immunocompromised patients. The most commonly affected patients are hematopoietic stem cell transplant recipients and patients with hematological malignancies undergoing intensive chemotherapy. The survival of patients with invasive pulmonary aspergillosis is very poor because of difficulties in early diagnosis and lack of effective treatment options. Research efforts are being made constantly to improve different diagnostic techniques. Early, repeated, high resolution computed tomography of the chest, and sequential nonculture-based monitoring of Aspergillus antigen and DNA can improve earlier diagnosis. New antifungal drugs for treatment and prevention of invasive pulmonary aspergillosis continue to emerge, with better safety, efficacy, and pharmacologic profiles.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981308     DOI: 10.1097/00063198-200205000-00008

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  17 in total

1.  Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.

Authors:  Faisal Usman; Jongdee Nopparat; Ibrahim Javed; Teerapol Srichana
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

2.  Aspergillus fumigatus does not require fatty acid metabolism via isocitrate lyase for development of invasive aspergillosis.

Authors:  Felicitas Schöbel; Oumaïma Ibrahim-Granet; Patrick Avé; Jean-Paul Latgé; Axel A Brakhage; Matthias Brock
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

3.  Aspergillus cyclooxygenase-like enzymes are associated with prostaglandin production and virulence.

Authors:  Dimitrios I Tsitsigiannis; Jin-Woo Bok; David Andes; Kristian Fog Nielsen; Jens C Frisvad; Nancy P Keller
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis.

Authors:  S Kaur; V K Gupta; S Thiel; P U Sarma; T Madan
Journal:  Clin Exp Immunol       Date:  2007-03-05       Impact factor: 4.330

5.  Use of mycological, nested PCR, and real-time PCR methods on BAL fluids for detection of Aspergillus fumigatus and A. flavus in solid organ transplant recipients.

Authors:  Hossein Zarrinfar; Hossein Mirhendi; Koichi Makimura; Kazuo Satoh; Hossein Khodadadi; Omolbanin Paknejad
Journal:  Mycopathologia       Date:  2013-09-18       Impact factor: 2.574

6.  Incidence of pulmonary aspergillosis and correlation of conventional diagnostic methods with nested PCR and real-time PCR assay using BAL fluid in intensive care unit patients.

Authors:  Hossein Zarrinfar; Koichi Makimura; Kazuo Satoh; Hossein Khodadadi; Hossein Mirhendi
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

7.  The Transcriptional Regulator HbxA Governs Development, Secondary Metabolism, and Virulence in Aspergillus fumigatus.

Authors:  Timothy Satterlee; Binita Nepal; Sophie Lorber; Olivier Puel; Ana M Calvo
Journal:  Appl Environ Microbiol       Date:  2020-01-21       Impact factor: 4.792

8.  VeA regulates conidiation, gliotoxin production, and protease activity in the opportunistic human pathogen Aspergillus fumigatus.

Authors:  Sourabh Dhingra; David Andes; Ana M Calvo
Journal:  Eukaryot Cell       Date:  2012-10-19

9.  Successful treatment of liver aspergilloma by caspofungin acetate first-line therapy in a non-immunocompromised patient.

Authors:  Qing-Xian Bai; Yi Huan; Jian-Hong Wang; Li-Jie Yang; Hong-Juan Dong
Journal:  Int J Mol Sci       Date:  2012-09-06       Impact factor: 6.208

10.  Mycological Microscopic and Culture Examination of 400 Bronchoalveolar Lavage (BAL) Samples.

Authors:  H Zarrinfar; S Saber; P Kordbacheh; K Makimura; A Fata; M Geramishoar; H Mirhendi
Journal:  Iran J Public Health       Date:  2012-07-31       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.